vs
Side-by-side financial comparison of Esperion Therapeutics, Inc. (ESPR) and SMITH & WESSON BRANDS, INC. (SWBI). Click either name above to swap in a different company.
Esperion Therapeutics, Inc. is the larger business by last-quarter revenue ($168.4M vs $124.7M, roughly 1.4× SMITH & WESSON BRANDS, INC.). On growth, Esperion Therapeutics, Inc. posted the faster year-over-year revenue change (143.7% vs -3.9%). Over the past eight quarters, Esperion Therapeutics, Inc.'s revenue compounded faster (10.6% CAGR vs -4.8%).
Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.
Smith & Wesson Brands, Inc. (S&W) is an American firearm manufacturer headquartered in Maryville, Tennessee, United States.
ESPR vs SWBI — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $168.4M | $124.7M |
| Net Profit | — | $1.9M |
| Gross Margin | — | 24.3% |
| Operating Margin | 50.6% | 3.3% |
| Net Margin | — | 1.5% |
| Revenue YoY | 143.7% | -3.9% |
| Net Profit YoY | — | -53.6% |
| EPS (diluted) | $0.32 | $0.04 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $168.4M | $124.7M | ||
| Q3 25 | $87.3M | $85.1M | ||
| Q2 25 | $82.4M | $140.8M | ||
| Q1 25 | $65.0M | $115.9M | ||
| Q4 24 | $69.1M | $129.7M | ||
| Q3 24 | $51.6M | $88.3M | ||
| Q2 24 | $73.8M | $159.1M | ||
| Q1 24 | $137.7M | $137.5M |
| Q4 25 | — | $1.9M | ||
| Q3 25 | $-31.3M | $-3.4M | ||
| Q2 25 | $-12.7M | $8.6M | ||
| Q1 25 | $-40.5M | $2.1M | ||
| Q4 24 | — | $4.5M | ||
| Q3 24 | $-29.5M | $-1.9M | ||
| Q2 24 | $-61.9M | $27.9M | ||
| Q1 24 | $61.0M | $7.9M |
| Q4 25 | — | 24.3% | ||
| Q3 25 | — | 25.9% | ||
| Q2 25 | — | 28.8% | ||
| Q1 25 | — | 24.1% | ||
| Q4 24 | — | 26.6% | ||
| Q3 24 | — | 27.4% | ||
| Q2 24 | — | 35.5% | ||
| Q1 24 | — | 28.7% |
| Q4 25 | 50.6% | 3.3% | ||
| Q3 25 | -11.4% | -3.5% | ||
| Q2 25 | 8.6% | 9.3% | ||
| Q1 25 | -34.0% | 4.1% | ||
| Q4 24 | -6.4% | 5.8% | ||
| Q3 24 | -31.0% | -1.7% | ||
| Q2 24 | 3.5% | 17.4% | ||
| Q1 24 | 52.5% | 8.2% |
| Q4 25 | — | 1.5% | ||
| Q3 25 | -35.9% | -4.0% | ||
| Q2 25 | -15.4% | 6.1% | ||
| Q1 25 | -62.2% | 1.8% | ||
| Q4 24 | — | 3.5% | ||
| Q3 24 | -57.2% | -2.1% | ||
| Q2 24 | -83.9% | 17.5% | ||
| Q1 24 | 44.3% | 5.7% |
| Q4 25 | $0.32 | $0.04 | ||
| Q3 25 | $-0.16 | $-0.08 | ||
| Q2 25 | $-0.06 | $0.19 | ||
| Q1 25 | $-0.21 | $0.05 | ||
| Q4 24 | $-0.14 | $0.10 | ||
| Q3 24 | $-0.15 | $-0.04 | ||
| Q2 24 | $-0.33 | $0.60 | ||
| Q1 24 | $0.34 | $0.17 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $167.9M | $22.4M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-302.0M | $363.2M |
| Total Assets | $465.9M | $548.6M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $167.9M | $22.4M | ||
| Q3 25 | $92.4M | $18.0M | ||
| Q2 25 | $86.1M | $25.2M | ||
| Q1 25 | $114.6M | $26.7M | ||
| Q4 24 | $144.8M | $39.1M | ||
| Q3 24 | $144.7M | $35.5M | ||
| Q2 24 | $189.3M | $60.8M | ||
| Q1 24 | $226.6M | $47.4M |
| Q4 25 | $-302.0M | $363.2M | ||
| Q3 25 | $-451.4M | $364.4M | ||
| Q2 25 | $-433.5M | $372.5M | ||
| Q1 25 | $-426.2M | $366.9M | ||
| Q4 24 | $-388.7M | $371.5M | ||
| Q3 24 | $-370.2M | $380.0M | ||
| Q2 24 | $-344.2M | $399.9M | ||
| Q1 24 | $-294.3M | $376.4M |
| Q4 25 | $465.9M | $548.6M | ||
| Q3 25 | $364.0M | $554.6M | ||
| Q2 25 | $347.1M | $559.6M | ||
| Q1 25 | $324.0M | $578.9M | ||
| Q4 24 | $343.8M | $587.4M | ||
| Q3 24 | $314.1M | $571.3M | ||
| Q2 24 | $352.3M | $577.4M | ||
| Q1 24 | $373.1M | $570.6M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $45.2M | $27.3M |
| Free Cash FlowOCF − Capex | — | $16.3M |
| FCF MarginFCF / Revenue | — | 13.1% |
| Capex IntensityCapex / Revenue | 0.0% | 8.8% |
| Cash ConversionOCF / Net Profit | — | 14.22× |
| TTM Free Cash FlowTrailing 4 quarters | — | $21.3M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $45.2M | $27.3M | ||
| Q3 25 | $-4.3M | $-8.1M | ||
| Q2 25 | $-31.4M | $40.8M | ||
| Q1 25 | $-22.6M | $-9.8M | ||
| Q4 24 | $-35.0M | $-7.4M | ||
| Q3 24 | $-35.3M | $-30.8M | ||
| Q2 24 | $-7.2M | $43.7M | ||
| Q1 24 | $53.8M | $25.2M |
| Q4 25 | — | $16.3M | ||
| Q3 25 | — | $-12.4M | ||
| Q2 25 | — | $33.5M | ||
| Q1 25 | — | $-16.1M | ||
| Q4 24 | — | $-10.7M | ||
| Q3 24 | $-35.5M | $-35.5M | ||
| Q2 24 | $-7.3M | $38.2M | ||
| Q1 24 | $53.8M | $7.0M |
| Q4 25 | — | 13.1% | ||
| Q3 25 | — | -14.6% | ||
| Q2 25 | — | 23.8% | ||
| Q1 25 | — | -13.9% | ||
| Q4 24 | — | -8.3% | ||
| Q3 24 | -68.7% | -40.2% | ||
| Q2 24 | -9.9% | 24.0% | ||
| Q1 24 | 39.0% | 5.1% |
| Q4 25 | 0.0% | 8.8% | ||
| Q3 25 | 0.0% | 5.0% | ||
| Q2 25 | 0.0% | 5.2% | ||
| Q1 25 | 0.0% | 5.4% | ||
| Q4 24 | 0.0% | 2.5% | ||
| Q3 24 | 0.3% | 5.3% | ||
| Q2 24 | 0.1% | 3.5% | ||
| Q1 24 | 0.1% | 13.2% |
| Q4 25 | — | 14.22× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 4.73× | ||
| Q1 25 | — | -4.68× | ||
| Q4 24 | — | -1.63× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 1.57× | ||
| Q1 24 | 0.88× | 3.20× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
SWBI
Segment breakdown not available.
